{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:28:09Z","timestamp":1793082489058,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ando.2023.01.008","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T22:12:09Z","timestamp":1677276729000},"page":"472-480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Congenital adrenal hyperplasia: New biomarkers and adult treatments"],"prefix":"10.1016","volume":"84","author":[{"given":"Bleuenn","family":"Dreves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2023.01.008_bib0250","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMra021561","article-title":"Congenital adrenal hyperplasia","volume":"349","author":"Speiser","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.01.008_bib0255","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ecl.2015.02.002","article-title":"Adrenal steroidogenesis and congenital adrenal hyperplasia","volume":"44","author":"Turcu","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2023.01.008_bib0260","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0265","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/gim.2017.46","article-title":"Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians","volume":"19","author":"Hannah-Shmouni","year":"2017","journal-title":"Genet Med."},{"key":"10.1016\/j.ando.2023.01.008_bib0270","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol."},{"key":"10.1016\/j.ando.2023.01.008_bib0275","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1210\/jc.2019-00449","article-title":"Continuous free cortisol profiles\u00a0\u2013\u00a0circadian rhythms in healthy men","volume":"104","author":"Bhake","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0280","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijpsycho.2008.03.014","article-title":"The cortisol awakening response (CAR): facts and future directions","volume":"72","author":"Fries","year":"2009","journal-title":"Psychophysiol"},{"key":"10.1016\/j.ando.2023.01.008_bib0285","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1210\/js.2019-00136","article-title":"Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"3","author":"Whittle","year":"2019","journal-title":"J Endocrine Soc"},{"key":"10.1016\/j.ando.2023.01.008_bib0290","first-page":"CD012517","article-title":"Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia","volume":"3","author":"Ng","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ando.2023.01.008_bib0295","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1210\/jc.2010-0917","article-title":"United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients","volume":"95","author":"Arlt","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0300","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1210\/jcem-70-3-642","article-title":"Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia","volume":"70","author":"Spritzer","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0305","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1210\/jc.2012-2102","article-title":"Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia","volume":"97","author":"Finkielstain","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0310","first-page":"e5247","article-title":"Cardiovascular disease risk factors and metabolic morbidity in a longitudinal study of congenital adrenal hyperplasia","volume":"106","author":"Torky","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0315","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1210\/jc.2018-01862","article-title":"Cardiovascular and metabolic outcomes in congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"103","author":"Tamhane","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0320","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1210\/JC.2015-2093","article-title":"Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study","volume":"100","author":"Falhammar","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0325","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3803\/EnM.2022.1528","article-title":"Long-term outcomes of congenital adrenal hyperplasia","volume":"37","author":"Nordenstr\u00f6m","year":"2022","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0330","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1210\/clinem\/dgaa801","article-title":"Reproductive and perinatal outcomes in women with congenital adrenal hyperplasia: a population-based cohort study","volume":"106","author":"Hirschberg","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0335","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.rbmo.2020.08.036","article-title":"Pregnancy, delivery and neonatal outcomes among women with congenital adrenal hyperplasia: a study of a large US database","volume":"41","author":"Badeghiesh","year":"2020","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ando.2023.01.008_bib0340","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1210\/jc.2007-0744","article-title":"Fractures and bone mineral density in adult women with 21-hydroxylase deficiency","volume":"92","author":"Falhammar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0345","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/EJE-16-0104","article-title":"Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"175","author":"Ceccato","year":"2016","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.ando.2023.01.008_bib0350","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-21-0794","article-title":"Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia","volume":"186","author":"Prete","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.ando.2023.01.008_bib0355","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-20-1093","article-title":"Gonadal dysfunction in congenital adrenal hyperplasia","volume":"184","author":"Claahsen-van","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.01.008_bib0360","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1210\/jc.2018-00217","article-title":"Bilateral adrenalectomy in congenital adrenal hyperplasia: a systematic review and meta-analysis","volume":"103","author":"MacKay","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0365","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1530\/EJE-20-0787","article-title":"Effects of mitotane on testicular adrenal rest tumors in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a retrospective series of five patients","volume":"184","author":"Bachelot","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.ando.2023.01.008_bib0370","series-title":"Hyperplasie cong\u00e9nitale des surr\u00e9nales par d\u00e9ficit en 21-hydroxylase. Protocole national de diagnostic et de soins pour les maladies rares","year":"2011"},{"key":"10.1016\/j.ando.2023.01.008_bib0375","doi-asserted-by":"crossref","first-page":"bvaa192","DOI":"10.1210\/jendso\/bvaa192","article-title":"11-oxygenated androgens useful in the setting of discrepant conventional biomarkers in 21-hydroxylase deficiency","volume":"5","author":"Jha","year":"2020","journal-title":"J Endocr Soc."},{"key":"10.1016\/j.ando.2023.01.008_bib0380","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/EJE-15-1181","article-title":"Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency","volume":"174","author":"Turcu","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.01.008_bib0385","first-page":"4589","article-title":"11-Ketotestosterone is the dominant circulating bioactive androgen during normal and premature adrenarche","volume":"103","author":"Rege","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0390","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1210\/jc.2016-3989","article-title":"11-oxygenated androgens arebiomarkers of adrenal volume and testicular adrenal rest tumors in 21-hydroxylase deficiency","volume":"102","author":"Turcu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0395","first-page":"2701","article-title":"Sex differences in 11-oxygenated androgen patterns across adulthood","volume":"102","author":"Davio","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0400","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jsbmb.2015.11.005","article-title":"Development of a novel cell based androgen screening model","volume":"156","author":"Carmela","year":"2016","journal-title":"J Steroid Biochem Mol Biol."},{"key":"10.1016\/j.ando.2023.01.008_bib0405","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41574-020-0336-x","article-title":"11-oxygenated androgens in health and disease","volume":"16","author":"Turcu","year":"2020","journal-title":"Nat Rev Endocrinol."},{"key":"10.1016\/j.ando.2023.01.008_bib0410","doi-asserted-by":"crossref","first-page":"751191","DOI":"10.3389\/fendo.2021.751191","article-title":"24-hour profiles of 11-oxygenated C19 steroids and D5-steroid sulfates during oral and continuous subcutaneous glucocorticoids in 21-hydroxylase deficiency","volume":"12","author":"Turcu","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ando.2023.01.008_bib0415","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-20-0129","article-title":"Androgen excess and diagnostic steroid biomarkers for nonclassic 21-hydroxylase deficiency without cosyntropin stimulation","volume":"183","author":"Turcu","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.01.008_bib0420","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2014-3809","article-title":"A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia","volume":"100","author":"Mallappa","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0425","first-page":"1797","article-title":"Modified-release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia","volume":"102","author":"Jones","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0430","doi-asserted-by":"crossref","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","article-title":"Modified-release hydrocortisone in congenital adrenal hyperplasia","volume":"106","author":"Merke","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0435","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1210\/jc.2016-1916","article-title":"A phase 2 Study of continuous subcutaneous hydrocortisone infusion in adults with congenital adrenal hyperplasia","volume":"101","author":"Nella","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0440","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1210\/clinem\/dgaa381","article-title":"A phase 2, multicenter study of Nevanimibe for the treatment of congenital adrenal hyperplasia","volume":"105","author":"El-Maouche","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0445","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1210\/jc.2014-1258","article-title":"Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency","volume":"99","author":"Auchus","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.01.008_bib0450","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-19-0905","article-title":"Abiraterone acetate treatment lowers 11-oxygenated androgens","volume":"182","author":"Wright","year":"2020","journal-title":"Eur J Endocrinol."},{"key":"10.1016\/j.ando.2023.01.008_bib0455","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0460","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/clinem\/dgab749","article-title":"Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"107","author":"Auchus","year":"2022","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0465","doi-asserted-by":"crossref","first-page":"e4666","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.ando.2023.01.008_bib0470","doi-asserted-by":"crossref","unstructured":"Kusnetzow A., Fowler M., Athanacio J., Reinhart G., Rico-Bautista E., Han S. SAT-364 non-peptide orally-bioavailable ACTH antagonists: suppression of ACTH-induced corticosterone secretion and adrenal hypertrophy in rats. J Endocr Soc 2019. doi: 10.1210\/js.2019-SAT-364. Published online 2019 Apr 30.","DOI":"10.1210\/js.2019-SAT-364"},{"key":"10.1016\/j.ando.2023.01.008_bib0475","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa046.690","article-title":"MON-176 discovery and identification of late stage selective non-peptide ACTH antagonists for the treatment of Cushing's disease? Ectopic ACTH secreting tumors, and congenital adrenal hyperplasia","volume":"4","author":"Kusnetzow","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2023.01.008_bib0480","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa046.699","article-title":"OR19-03 effects of non-peptide orally bioavailable ACTH antagonists on adrenal gland size and function in rats","volume":"4","author":"Markison","year":"2020","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2023.01.008_bib0485","first-page":"1","article-title":"ALD1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology","volume":"158","author":"Feldhaus","year":"2017","journal-title":"Endocrinology."},{"key":"10.1016\/j.ando.2023.01.008_bib0490","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/clinem\/dgaa438","article-title":"New horizons: novel adrenal regenerative therapies","volume":"105","author":"Bornstein","year":"2020","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:54:33Z","timestamp":1757717673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426623000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0003426623000343"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.01.008","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Congenital adrenal hyperplasia: New biomarkers and adult treatments","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}